Tag: SGEN

Gilead Sciences GILD NASDAQ:GILD
Finance

Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

MannKind Corporation (NASDAQ:MNKD) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.MannKind Corporation (NASDAQ:MNKD) stock performance was -6.42% in last session and finished the day at … Continue reading Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

Kristen Barton
Finance

Top News: United States Steel Corp. (NYSE:X), Seattle Genetics Inc. (NASDAQ:SGEN), Naugatuck Valley Financial Corporation (NASDAQ:NVSL), National CineMedia (NASDAQ:NCMI), SK Telecom (NYSE:SKM)

On Oct 28, United States Steel Corp. (NYSE:X) posted a narrower loss, as revenue increased and the company said U.S. market conditions have remained stable. For the quarter ended Sept. 30, the company posted a loss of $207 million, or $1.42 a share, compared with a loss of $1.79 billion, or $12.38 a share, a year earlier, which reflected a $1.78 billion impairment charge. United … Continue reading Top News: United States Steel Corp. (NYSE:X), Seattle Genetics Inc. (NASDAQ:SGEN), Naugatuck Valley Financial Corporation (NASDAQ:NVSL), National CineMedia (NASDAQ:NCMI), SK Telecom (NYSE:SKM)

Kevin Long
Finance

Shining on Major News: MannKind Corp. (NASDAQ:MNKD), Exelon Corporation (NYSE:EXC), Coca-Cola Company (NYSE:KO), Seattle Genetics (NASDAQ:SGEN), Yum! Brands, Inc. (NYSE:YUM)

On August 11,2014 MannKind Corp. (NASDAQ:MNKD) reported financial results for the second quarter ended June 30, 2014. For the second quarter of 2014, total operating expenses were $69.8 million, compared to $41.6 million for the second quarter of 2013, an increase of $28.2 million, largely due to an increase in non-cash stock compensation expense of $30.5 million. MannKind Corp. (NASDAQ:MNKD) belongs to Healthcare sector. Its … Continue reading Shining on Major News: MannKind Corp. (NASDAQ:MNKD), Exelon Corporation (NYSE:EXC), Coca-Cola Company (NYSE:KO), Seattle Genetics (NASDAQ:SGEN), Yum! Brands, Inc. (NYSE:YUM)

Chris Lewis
Finance

Trending Stocks : Ariad Pharmaceuticals (NASDAQ:ARIA), Checkpoint (NYSE:CKP), Computer Sciences (NYSE:CSC), Seattle Genetics Inc. (NASDAQ:SGEN), Infoblox Inc. (NYSE:BLOX)

US specialty pharma firm Ariad Pharmaceuticals (NASDAQ:ARIA) has granted Israel’s Medison Pharma exclusive rights to commercialize Iclusig (ponatinib) in Israel for patients with Philadelphia-positive (Ph+) leukemias. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Healthcare sector. Its weekly performance is -12.09%. On last trading day company shares ended up $5.38. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -12.94%. Checkpoint Systems, Inc. (NYSE:CKP) … Continue reading Trending Stocks : Ariad Pharmaceuticals (NASDAQ:ARIA), Checkpoint (NYSE:CKP), Computer Sciences (NYSE:CSC), Seattle Genetics Inc. (NASDAQ:SGEN), Infoblox Inc. (NYSE:BLOX)

Mark Doerr
Finance

Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on July 9 announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts. Ultragenyx is selling 1,311,277 shares of its common stock in this offering, and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) … Continue reading Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Adam Keintzel